China Market Research Reports adds “Research Report on China Blood Product Industry, 2011-2016” to its store.
A Blood products made by segregating and purifying all kinds of proteins in the blood plasma consists of albumin, immunoglobulin, thrombinogen and other products. China's enterprises mainly produce 9 kinds of products in the first three categories. The high concentration rate of the global blood product market is embodied in the three companies of developed countries accounting for more than 80% of the global market. The current global blood market remains relatively stable, of which the emerging economy is the main motivation of growth. By the end of 2015, there were 33 blood product manufacturing enterprises certified by the government in China, but in fact, only 20 of them were in production. Since 2012, mergers and acquisitions are common in China's blood product industry. For example, Jiangxi Boya Bio-Pharmaceutical Co., Ltd. acquired partial stock rights of Zhejiang Haikang Biologicals Co., Ltd. Beijing Tiantan Biological Products Co., Ltd. purchased Chengdu Rosen Pharmaceutical Co., Ltd. Watson Biological Company acquired Hebei Docan Pharmaceutical Co., Ltd. Shanghai RAAS Blood Products Co., Ltd. purchased Zhengzhou Banghe Pharmaceutical Co., Ltd. China National Biotec Group acquired Guiyang Qianfeng Biological Products Co., Ltd. and Xi'an Huitian Blood Products Co., Ltd. Humanwell Healthcare Group Co., Ltd. purchased Wuhan Rui De Biological Products Co., Ltd.
Inquire for Discount @ http://www.chinamarketresearchreports.com/contacts/inquiry.php?name=115338
In 2015, 8,000 tons of blood plasma was needed to meet the demand of Chinese market, and the actual supply was only 5,000 tons. For example, the demand for blood products of about 1.4 billion population of China should be 12,000 tons calculated according to per capita demand of the normal blood products of the World Health Organization, which is far more than the actual supply of China. In China's blood product industry, the scale of the blood plasma has been the main bottleneck restricting the development of blood product industry. The quality and quantity of plasma stations are of vital importance. In 2001, Chinese government announced that no new blood product manufacturing enterprises would be approved to ensure the safety of blood and its products, and block the spread of HIV through collection and supply of blood . In 2008, Chinese government formulated the regulations that the plasma collection regions should guarantee the quantity of the plasma donors, which can satisfy no less than 30 tons' collection of source plasma.
Order a copy of this report @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=115338
In 2011, Guizhou government announced the program of adjusting the settings of blood services. The plasma collection stations decreased from 20 to 4, of which Hualan Biological Engineering Co., Ltd., the blood product giant, suffered the most. The plasma stations of Guizhou Province decreased from 6 to 1, having reduced half of the corporate source plasma supply.
Lack of the local blood products, but Chinese government has issued strict regulations on the import of blood products. Only human serum albumin and three kinds of thrombinogen are allowed to be imported. In recent years, the competitiveness of China's blood product market has been mainly determined by the amount of blood plasma resources. Under the tense condition of source plasma supply, blood product manufacturing enterprises will obtain more space for survival and development with more blood plasma stations and source plasma.
More Reports of Life Sciences Industry @ http://www.chinamarketresearchreports.com/cat/life-sciences.html
China Market Research Reports
China market research reports portal aims at providing business intelligence, market research, company research, investment consultation and other market intelligence data for multiple industries in China. The reports available through our website are from publishers that focus on meeting research and information requirements of corporate, businesses, institutions, and global professional investors for IPO, corporate mergers and acquisition, business development, market launch, financing and more. These China reports are helpful for strategic formulation, forecasting, risk management, and investment research with all the available data and information analysis, saving time and money for businesses and clients. Feel free to get in touch with us (firstname.lastname@example.org / +1 888 391 5441) with your specific requirements, topics of interest or anything that you are not able to find on our portal.
P: + 1 888 391 5441